Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001136261-19-000264
Filing Date
2019-11-07
Accepted
2019-11-07 16:20:27
Documents
52
Period of Report
2019-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q body10q.htm 10-Q 576567
2 AMENDMENT NO. 2 TO ASSET PURCHASE AGREEMENT, DATED AS OF DECEMBER 31, 2018, BY A exh10-1.htm EX-10.1 9336
3 AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT, DATED AUGUST 29, 2019, BY AND exh10-7.htm EX-10.7 51227
4 302 CERTIFICATE exh31-1.htm EX-31.1 7475
5 906 CERTIFICATE exh32-1.htm EX-32.1 2595
  Complete submission text file 0001136261-19-000264.txt   3306986

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT seel-20190930.xml EX-101.INS 379241
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT seel-20190930.xsd EX-101.SCH 58770
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT seel-20190930_cal.xml EX-101.CAL 70290
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT seel-20190930_def.xml EX-101.DEF 234005
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT seel-20190930_lab.xml EX-101.LAB 416800
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT seel-20190930_pre.xml EX-101.PRE 370431
Mailing Address 300 PARK AVENUE NEW YORK NY 10017
Business Address 300 PARK AVENUE NEW YORK NY 10017 (646) 998-6475
SEELOS THERAPEUTICS, INC. (Filer) CIK: 0001017491 (see all company filings)

EIN.: 870449967 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-22245 | Film No.: 191200631
SIC: 2834 Pharmaceutical Preparations